Lotus Eye Hospital and Institute Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lotus Eye Hospital and Institute.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	26.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lotus Eye Hospital and Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:LOTUSEYE - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	485	35	N/A	N/A	N/A
9/30/2023	486	40	-1	57	N/A
6/30/2023	477	41	N/A	N/A	N/A
3/31/2023	470	41	13	44	N/A
12/31/2022	464	40	N/A	N/A	N/A
9/30/2022	459	42	13	69	N/A
6/30/2022	449	46	N/A	N/A	N/A
3/31/2022	389	30	-3	44	N/A
12/31/2021	389	36	N/A	N/A	N/A
9/30/2021	372	32	37	49	N/A
6/30/2021	335	20	N/A	N/A	N/A
3/31/2021	324	16	23	27	N/A
12/31/2020	300	-5	N/A	N/A	N/A
9/30/2020	301	-14	8	26	N/A
6/30/2020	335	-6	N/A	N/A	N/A
3/31/2020	406	11	26	50	N/A
12/31/2019	420	21	N/A	N/A	N/A
9/30/2019	415	20	N/A	N/A	N/A
6/30/2019	401	11	N/A	N/A	N/A
3/31/2019	384	7	-5	42	N/A
12/31/2018	382	7	N/A	N/A	N/A
9/30/2018	381	9	N/A	N/A	N/A
6/30/2018	384	14	N/A	N/A	N/A
3/31/2018	380	17	15	58	N/A
12/31/2017	373	8	N/A	N/A	N/A
9/30/2017	359	4	N/A	N/A	N/A
6/30/2017	350	6	N/A	N/A	N/A
3/31/2017	340	4	N/A	30	N/A
12/31/2016	330	7	N/A	N/A	N/A
9/30/2016	324	7	N/A	N/A	N/A
6/30/2016	314	0	N/A	N/A	N/A
3/31/2016	311	1	N/A	34	N/A
12/31/2015	311	-5	N/A	N/A	N/A
9/30/2015	315	-6	N/A	N/A	N/A
6/30/2015	308	-14	N/A	N/A	N/A
3/31/2015	302	-20	N/A	24	N/A
12/31/2014	298	-12	N/A	N/A	N/A
9/30/2014	290	-9	N/A	N/A	N/A
6/30/2014	289	1	N/A	N/A	N/A
3/31/2014	288	0	N/A	44	N/A
12/31/2013	287	4	N/A	N/A	N/A
9/30/2013	285	2	N/A	N/A	N/A
6/30/2013	289	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LOTUSEYE's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if LOTUSEYE's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if LOTUSEYE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LOTUSEYE's Return on Equity is forecast to be high in 3 years time

Lotus Eye Hospital and Institute Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Vice President of Administration recently sold ₹173m worth of stock

Investor sentiment deteriorates as stock falls 24%

Lotus Eye Hospital and Institute Limited to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2024 earnings released: EPS: ₹0.32 (vs ₹0.56 in 3Q 2023)

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Vice President of Administration recently sold ₹18m worth of stock

Second quarter 2024 earnings released: EPS: ₹0.41 (vs ₹0.43 in 2Q 2023)

Investor sentiment improves as stock rises 18%

Upcoming dividend of ₹0.50 per share at 0.6% yield

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹0.67 (vs ₹0.66 in 1Q 2023)

Lotus Eye Hospital and Institute Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 23%

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Full year 2023 earnings released: EPS: ₹1.96 (vs ₹1.44 in FY 2022)

Lotus Eye Hospital and Institute Limited Recommends Final Dividend for the Financial Year 2022-23

Investor sentiment improves as stock rises 21%

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.67 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.60 in 2Q 2022)

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: EPS: ₹0.66 (vs ₹0.09 loss in 1Q 2022)

Investor sentiment improved over the past week

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹1.44 (vs ₹0.75 in FY 2021)

Lotus Eye Hospital and Institute Limited Announces Appointment of Ramanujam Reghunathan as Chief Financial Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Lotus Eye Hospital and Institute Limited Appoints M Achuth Menon as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹0.50 per share

First quarter 2022 earnings released: ₹0.09 loss per share (vs ₹0.32 loss in 1Q 2021)

Full year 2021 earnings released: EPS ₹0.75 (vs ₹0.51 in FY 2020)

CEO & Additional Executive Director recently bought ₹2.0m worth of stock

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

MD & Whole Time Director recently bought ₹240k worth of stock

New 90-day high: ₹39.75

Lotus Eye Hospital and Institute Limited Announces Executive Appointments

Third quarter 2021 earnings released: EPS ₹0.51 (vs ₹0.08 in 3Q 2020)

Lotus Eye Hospital and Institute Limited Announces Demise of Founder Dr. S.K. Sundaramoorthy

New 90-day high: ₹37.90

New 90-day high: ₹34.40

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer recently bought ₹2.0m worth of stock

New 90-day high: ₹32.90

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

MD & Whole Time Director recently bought ₹198k worth of stock

Second quarter 2021 earnings released: EPS ₹0.04

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Nov 28, 2020

Lotus Eye Hospital and Institute Limited to Report First Half, 2021 Results on Nov 11, 2020

Chief Executive Officer recently bought ₹229k worth of stock

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

First quarter earnings released

First quarter earnings released

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

New 90-day high - ₹35.05

Lotus Eye Hospital and Institute Limited to Report Q1, 2021 Results on Aug 31, 2020

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies